Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Acumen Pharmaceuticals, Inc. (ABOS : NSDQ)

• Company Description    Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $1.30 Daily Weekly Monthly 20 Day Moving Average: 542,138 shares Shares Outstanding: 60.57 (millions) Market Capitalization: $78.75 (millions) Beta: 0.11 52 Week High: $3.60 52 Week Low: $0.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.03% 9.76% 12 Week 44.32% 21.39% Year To Date -24.42% -29.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1210-1220 WASHINGTON ST. SUITE 210 - Newton,MA 22902 USA ph: 617-344-4190 fax: - investors@acumenpharm.com http://www.acumenpharm.com

• General Corporate Information    Officers Daniel O'Connell - Chief Executive Officer and Director William Matthew Zuga - Chief Financial Officer and Chief Business Officer Kimberlee C. Drapkin - Director Nathan B. Fountain - Director Jeffrey L. Ives - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00509G209 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 60.57 Most Recent Split Date: (:1) Beta: 0.11 Market Capitalization: $78.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 5.13% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.51 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -92.00% vs. Previous Quarter: 22.58% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -58.24 12/31/24 - -45.23 ROA 06/30/25 - - 03/31/25 - -46.53 12/31/24 - -37.35 Current Ratio 06/30/25 - - 03/31/25 - 8.02 12/31/24 - 6.46 Quick Ratio 06/30/25 - - 03/31/25 - 8.02 12/31/24 - 6.46 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.57 12/31/24 - 3.03 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.19 12/31/24 - 0.16 Debt-to-Capital 06/30/25 - - 03/31/25 - 15.96 12/31/24 - 13.93

Powered by Zacks Investment Research ©